GlassScriptPhysician profile
Danielle R Smith
NPI 1164826749
$1,900.60
in general payments reported to CMS, 2019-2025
22 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $284 · 2023: $431 · 2024: $417 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.63 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.52 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $169.63 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $145.37 | 2021-2022 | |
| Lilly USA, LLC | $144.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $138.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $122.51 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.87 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $111.39 | 2021-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $75.08 | 2021-2022 | |
| Pfizer INC. | $65.99 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.79 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $62.83 | 2021-2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $51.03 | 2022-2025 | |
| Dexcom, INC. | $47.00 | 2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $43.17 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $20.50 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.36 | 2024 | Gvoke Hypopen |
| Mylan Specialty L.P. | $15.76 | 2024 | Yupelri |
| Eisai INC. | $15.61 | 2022 | |
| Cranial Technologies, INC | $15.60 | 2024 | Doc Band |
| Janssen Pharmaceuticals, INC | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.